AstraZeneca, Eli Lilly to continue trial for people with early Alzheimer's
April 08, 2016 at 08:30 AM EDT
AstraZeneca and Eli Lilly announced that Amaranth, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for early Alzheimer's disease, will continue into Phase III.
